sodium-morrhuate and Esophageal-Neoplasms

sodium-morrhuate has been researched along with Esophageal-Neoplasms* in 4 studies

Reviews

1 review(s) available for sodium-morrhuate and Esophageal-Neoplasms

ArticleYear
Squamous cell carcinoma after endoscopic injection sclerotherapy for esophageal varices.
    The American journal of gastroenterology, 1990, Volume: 85, Issue:7

    We report two cases of squamous cell carcinoma of the esophagus following endoscopic injection sclerotherapy for esophageal varices. The interval between sclerotherapy and the development of carcinoma was 24 months in case 1 and 21 months in case 2. The sclerosant was 5% sodium morrhuate in case 1 (total dose, 10 ml) and 5% ethanolamine oleate in case 2 (45.5 ml). Although no recurrent variceal bleeding occurred after sclerotherapy, we could not perform any curative surgical treatment for esophageal cancer because of the advanced stage of the cancer and the severity of the accompanying liver dysfunction. It is difficult to determine the relationship between sclerotherapy and carcinoma; however, long-term surveillance is essential to avoid overlooking a neoplasm in the esophagus after endoscopic injection sclerotherapy.

    Topics: Carcinoma, Squamous Cell; Esophageal and Gastric Varices; Esophageal Neoplasms; Esophagoscopy; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Oleic Acids; Sclerosing Solutions; Sclerotherapy; Sodium Morrhuate; Time Factors

1990

Other Studies

3 other study(ies) available for sodium-morrhuate and Esophageal-Neoplasms

ArticleYear
Development of squamous cell carcinoma of the esophagus after endoscopic variceal sclerotherapy.
    The American journal of gastroenterology, 1988, Volume: 83, Issue:5

    We describe the case of a 45-yr-old white male with portal hypertension and presumed Laennec's cirrhosis who developed squamous cell carcinoma of the esophagus 8 months after completion of a course of endoscopic variceal sclerotherapy. The epidemiology and natural history of esophageal cancer and their relationship to our patient are analyzed. This report emphasizes that squamous cell carcinoma of the esophagus should be considered in the differential diagnosis of postsclerotherapy dysphagia. Further studies will be required to determine whether or not esophageal variceal sclerotherapy is associated coincidently or causally with the development of squamous cell carcinoma of the esophagus in patients at increased risk for this condition.

    Topics: Carcinoma, Squamous Cell; Esophageal and Gastric Varices; Esophageal Neoplasms; Esophagoscopy; Fatty Acids; Humans; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Radiography; Sodium Morrhuate

1988
[A case of carcinoma of the esophagus developing two years after endoscopic injection sclerotherapy of esophageal varices].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1985, Volume: 82, Issue:7

    Topics: Carcinoma, Squamous Cell; Esophageal and Gastric Varices; Esophageal Neoplasms; Fatty Acids; Humans; Male; Middle Aged; Sclerosing Solutions; Sodium Morrhuate

1985
Computed tomography of esophageal varices after sclerotherapy.
    AJR. American journal of roentgenology, 1983, Volume: 140, Issue:6

    Topics: Aged; Diagnosis, Differential; Esophageal and Gastric Varices; Esophageal Neoplasms; Esophagoscopy; Esophagus; Fatty Acids; Humans; Male; Sodium Morrhuate; Tomography, X-Ray Computed

1983